Low Prices Cause Breast Cancer Drug Shortage In Turkey

Low prices for drugs in Turkey, due in part to official exchange rates used to set local prices, have long been a problem, but the issue has come to a new head following serious shortages for a breast cancer therapy.

Turkey
Tamoxifen shortage hits Turkey breast cancer patients. • Source: Shutterstock

Some breast cancer patients are facing a difficult situation in Turkey given recent local shortages of tamoxifen, which is used to treat hormone receptor-positive disease and is a first choice in the country for premenopausal women needing treatment. The estrogen-blocking drug is also used in postmenopausal women with breast cancer who cannot be treated with aromatase inhibitors.

For at least three months now, it has been very difficult to find generic tamoxifen, which is produced and imported...

Welcome to Pink Sheet

Create an account to read this article

More from Europe

Merck, AstraZeneca Downplay Impact of European Tariffs Despite Timing Uncertainties

 
• By 

Meanwhile, companies continue discussions with the Trump Administration over ways of increasing what European nations pay for drugs as an alternative to imposing a Most Favored Nation drug pricing policy in the US.

EU 2025 Novel Drug Approvals See Conditional Authorizations Outpacing Previous Years

 

The six EU conditional marketing authorizations granted in the first half of 2025 alone equal the full count for 2024 and come close to the annual totals for the previous two years. Meanwhile, H1 2025 saw a 30% rise in new active substance approvals compared to the same period last year.

New EU Drug Safety Rules Scrap Signal Detection Pilot, Boost Audit & Subcontracting Controls

 
• By 

The European Commission has adopted new rules to cut red tape in pharmacovigilance, tighten oversight of outsourced drug safety activities, and ensure a balanced approach to signal detection, boosting both efficiency and patient safety.

EU 15% Tariff Deal Still Leaves Questions For Pharma On Possible Grace Period, Generic Exemption

 

While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.

More from Geography

EU 15% Tariff Deal Still Leaves Questions For Pharma On Possible Grace Period, Generic Exemption

 

While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.

Medicare Part B ASP Proposal Sets ‘Guardrails’ Around Bona Fide Service Fee Reporting

 
• By 

Average sales prices, and Medicare spending on some drugs, would be expected to be lower, CMS says in the Physician Fee Schedule proposed rule.

A Record Year For US FDA Approvals? Commissioner Says It’s Possible

 

FDA Commissioner Martin Makary suggested 60 new molecular entities could be approved in 2025, which appears possible, but can the strained staff deliver?